menu

Our news

HomeOur news
HomeOur news

Our company news

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.

...

more

23 Mar , 16
Press Release, Moscow, October, 2014

Press Release, Moscow, October, 2014

Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta

...

more

01 Oct , 14
Press Release, Moscow, March 15th, 2012

Press Release, Moscow, March 15th, 2012

Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program

Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds

...

more

15 Mar , 12